PURPOSE: Complications and functional outcomes after prostate surgery vary among surgeons to a greater extent than may be accounted for by chance. This excessive variation is known as heterogeneity. We explored whether there is also heterogeneity among high volume surgeons with respect to cancer control after surgery. MATERIALS AND METHODS: The study cohort consisted of 7,725 patients with clinically localized prostate cancer treated with open radical prostatectomy at 4 major American academic medical centers from 1987 to 2003 by 1 of 54 surgeons. We defined biochemical recurrence as serum prostate specific antigen 0.4 ng/ml or greater followed by a higher level. Multivariate random effects models were used to evaluate prostate cancer recurrence heterogeneity among surgeons after adjusting for case mix (prostate specific antigen, pathological stage and grade), surgery year and surgeon experience. RESULTS: We found statistically significant heterogeneity in the prostate cancer recurrence rate independent of surgeon experience (p = 0.002). Seven experienced surgeons had an adjusted 5-year prostate cancer recurrence rate of less than 10% while another 5 had a rate that exceeded 25%. Significant heterogeneity remained on sensitivity analysis adjusting for possible differences in followup, patient selection and stage migration. CONCLUSIONS: Patient risk of recurrence may differ depending on which of 2 surgeons is seen even if the surgeons have similar experience levels. Surgical randomized trials are imperative to determine and characterize the roots of these variations. 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
PURPOSE: Complications and functional outcomes after prostate surgery vary among surgeons to a greater extent than may be accounted for by chance. This excessive variation is known as heterogeneity. We explored whether there is also heterogeneity among high volume surgeons with respect to cancer control after surgery. MATERIALS AND METHODS: The study cohort consisted of 7,725 patients with clinically localized prostate cancer treated with open radical prostatectomy at 4 major American academic medical centers from 1987 to 2003 by 1 of 54 surgeons. We defined biochemical recurrence as serum prostate specific antigen 0.4 ng/ml or greater followed by a higher level. Multivariate random effects models were used to evaluate prostate cancer recurrence heterogeneity among surgeons after adjusting for case mix (prostate specific antigen, pathological stage and grade), surgery year and surgeon experience. RESULTS: We found statistically significant heterogeneity in the prostate cancer recurrence rate independent of surgeon experience (p = 0.002). Seven experienced surgeons had an adjusted 5-year prostate cancer recurrence rate of less than 10% while another 5 had a rate that exceeded 25%. Significant heterogeneity remained on sensitivity analysis adjusting for possible differences in followup, patient selection and stage migration. CONCLUSIONS:Patient risk of recurrence may differ depending on which of 2 surgeons is seen even if the surgeons have similar experience levels. Surgical randomized trials are imperative to determine and characterize the roots of these variations. 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Authors: Anna Bill-Axelson; Lars Holmberg; Mirja Ruutu; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Christer Busch; Stig Nordling; Hans Garmo; Juni Palmgren; Hans-Olov Adami; Bo Johan Norlén; Jan-Erik Johansson Journal: N Engl J Med Date: 2005-05-12 Impact factor: 91.245
Authors: Peter Swindle; James A Eastham; Makoto Ohori; Michael W Kattan; Thomas Wheeler; Norio Maru; Kevin Slawin; Peter T Scardino Journal: J Urol Date: 2005-09 Impact factor: 7.450
Authors: Michel Bolla; Hein van Poppel; Laurence Collette; Paul van Cangh; Kris Vekemans; Luigi Da Pozzo; Theo M de Reijke; Antony Verbaeys; Jean-François Bosset; Roland van Velthoven; Jean-Marie Maréchal; Pierre Scalliet; Karin Haustermans; Marianne Piérart Journal: Lancet Date: 2005 Aug 13-19 Impact factor: 79.321
Authors: Felix K-H Chun; Alberto Briganti; Elie Antebi; Markus Graefen; Eike Currlin; Thomas Steuber; Thorsten Schlomm; Jochen Walz; Alexander Haese; Martin G Friedrich; Sascha A Ahyai; Christian Eichelberg; Georg Salomon; Andrea Gallina; Andreas Erbersdobler; Paul Perrotte; Hans Heinzer; Hartwig Huland; Pierre I Karakiewicz Journal: BJU Int Date: 2006-10-11 Impact factor: 5.588
Authors: Andrew J Stephenson; Michael W Kattan; James A Eastham; Zohar A Dotan; Fernando J Bianco; Hans Lilja; Peter T Scardino Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: Andrew J Vickers; Fernando J Bianco; Mithat Gonen; Angel M Cronin; James A Eastham; Deborah Schrag; Eric A Klein; Alwyn M Reuther; Michael W Kattan; J Edson Pontes; Peter T Scardino Journal: Eur Urol Date: 2008-01-14 Impact factor: 20.096
Authors: Andrew J Vickers; Fernando J Bianco; Angel M Serio; James A Eastham; Deborah Schrag; Eric A Klein; Alwyn M Reuther; Michael W Kattan; J Edson Pontes; Peter T Scardino Journal: J Natl Cancer Inst Date: 2007-07-24 Impact factor: 13.506
Authors: Sharlene Gill; Charles L Loprinzi; Daniel J Sargent; Stephan D Thomé; Steven R Alberts; Daniel G Haller; Jacqueline Benedetti; Guido Francini; Lois E Shepherd; Jean Francois Seitz; Roberto Labianca; Wei Chen; Stephen S Cha; Michael P Heldebrant; Richard M Goldberg Journal: J Clin Oncol Date: 2004-04-05 Impact factor: 44.544
Authors: Andrew J Vickers; Daniel Sjoberg; Ethan Basch; Frank Sculli; Marwan Shouery; Vincent Laudone; Karim Touijer; James Eastham; Peter T Scardino Journal: Eur Urol Date: 2011-11-04 Impact factor: 20.096
Authors: Quoc-Dien Trinh; Anders Bjartell; Stephen J Freedland; Brent K Hollenbeck; Jim C Hu; Shahrokh F Shariat; Maxine Sun; Andrew J Vickers Journal: Eur Urol Date: 2013-04-19 Impact factor: 20.096
Authors: Nicola Fossati; Niccolò M Passoni; Marco Moschini; Giorgio Gandaglia; Alessandro Larcher; Massimo Freschi; Giorgio Guazzoni; Daniel D Sjoberg; Andrew J Vickers; Francesco Montorsi; Alberto Briganti Journal: BJU Int Date: 2015-06-10 Impact factor: 5.588
Authors: C B Anderson; E B Elkin; C L Atoria; J A Eastham; P T Scardino; K Touijer Journal: Prostate Cancer Prostatic Dis Date: 2014-12-16 Impact factor: 5.554
Authors: Jonathan L Silberstein; Daniel Su; Leonard Glickman; Matthew Kent; Gal Keren-Paz; Andrew J Vickers; Jonathan A Coleman; James A Eastham; Peter T Scardino; Vincent P Laudone Journal: BJU Int Date: 2013-02 Impact factor: 5.588
Authors: Rebecka Arnsrud Godtman; Erik Persson; Walter Cazzaniga; Fredrik Sandin; Stefan Carlsson; Göran Ahlgren; Eva Johansson; David Robinsson; Jonas Hugosson; Pär Stattin Journal: PLoS One Date: 2021-06-17 Impact factor: 3.240